Abstract
Diabetes is the most important cause of end stage renal disease (ESRD) in the United States. Over 50% of all new patients entering ESRD programs are now diabetics and over one-third of the entire ESRD population of over 300,000 persons has diabetes mellitus as a cause of renal failure.1 The increase in diabetics as a percentage of all patients developing ESRD has been about 2% annually with no indication of a future decline. The ESRD program cost now exceeds 16 billion dollars annually. The exact percentage of patients with type 1 and type 2 diabetes who will progress to ESRD has been debated. From 25–40% of type 1 patients will develop nephropathy and most will progress to ESRD.2 If a type 1 diabetic has not developed proteinuria at 20–25 years, the risk of renal disease decreases to only a few percent. Of type 2 diabetes patients a smaller percentage will progress to ESRD. Nevertheless, since type 2 diabetics make up a far greater percentage of the overall diabetic population, the total number of diabetics who progress to ESRD is weighted towards type 2 rather than type 1 patients. Moreover, with improved treatment of hypertension and coronary heart disease, more type 2 diabetics are surviving long enough to develop ESRD. White patients have a lower risk of developing ESRD than do Blacks, Hispanics, or native Americans with type 2 diabetes. Almost 50% of diabetic Pima Indians develop nephropathy by 20 years of diabetes and 15% will have progressed by this time to ESRD.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
United States Renal Data System, USRDS 2000 Annual Data Report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD, June 2000.
Breyer J. Diabetic Nephropathy. In: Greenberg A ed: Primer on kidney diseases 2nd ed. Academic Press, New York, 215–220, 1998.
Mogenson CE, Keane WF, Bennett PH, et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 346: 1080–1084, 1995.
Bennett PH, Haffner S, Kasiske BL, Keane W, Mogensen CE, Parving HH, Steffes MW, Striker GE. Screening and management of microalbuminuria in patients with diabetes. Amer J Kidney disease 25: 107–112, 1995.
Wolf RA, Ashby VB, Milford EL, Ojo AO, Ettenger RA, Agodoa L, Held PJ, Port FK. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplant, and recipients of a first cadaveric transplant. N Engl J Med 341: 1725–1730, 1999.
Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med 329: 977–986, 1993.
Okhubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents progression of microvascular complications in Japanese patients with NIDDM: a randomized prospective six year study. Diab Res Clin Pract 28: 103–117, 1995.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications with type 2 diabetes. Lancet 352: 837–853, 1998.
Parving 11H, Anderson AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduced rate of decline in renal function in diabetic nephropathy. Lancet 1 (8335): 1175–1179, 1983.
UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. Brit Med J 317: 703–713, 1998.
American Diabetes Association Treatment of Hypertension in Diabetes (Consensus Statement). Diabetes Care 19 (Suppl 1): S107 - S113, 1996.
The Sixth Report of the Joint national Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Int Med 157: 2413–2446, 1997.
Remuzzi A, Perico N, Amuchastegui CS, Malanchini B, Mazerska M, Battaglia C, Bertani T, Remuzzi G. Short and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Amer Soc Nephr 4: 40–49, 1993.
Lewis EJ, Hunsicker L, Bain RP, et al. The effect of angiotensinconverting enzyme inhibition on diabetic nephropathy. N Eng J Med 329: 1456–1462, 1993.
Ravid M, Savin H, Jutrin I, Bental T, Kats B, Lishner M. Long-term stabilizing effect of ACE inhibition on plasma creatinine and on proteinuria in type 2 diabetic patients. Ann Int Med 118: 577–581, 1993.
Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of ACE inhibition in NIDDM: A 7 year follow-up study. Arch Int Med 156: 286–289, 1996.
Maschio G, Alberti D, Janin J, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Janin G, Zucchelli P, Angiotensin-Converting Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334: 939–945, 1996.
The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomized placebo controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349: 1857–1863, 1997.
HOPE Investigators. Effects Of ACE inhibitor ramipril on cardiovascular events in high risk patients. N Engl J Med 342: 145–153, 2000.
Pitt B, Segal R, Martinez FA, et al. Randomized trial of losartan versus captopril in patients over sixty five with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349: 747–752, 1997.
Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure- ELITE II. The Lancet 355: 1582–1587, 2000.
Bakris GL, Siomos M, Richardson D, et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kid Int 58: 2084–2092, 2000.
LaCourciere Y, Belanger A, Godin C et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kid Int 58: 762–769, 2000.
Parving HH, Lehnert H, Brochner-Mortensen J, et al, with the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870–878, 2001.
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S and the RENAAL Study Investigators. Effect of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N Engl J Med 345: 861–869, 2001.
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I with the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N Engl J Med 345: 851–860, 2001.
Russo D, Pisano A, Belleta MM, et al. Additive antiproteinuric effect of ACE inhibitor and losartan in normotensive patients with IgA Nephropathy. Amer J of Kid Dis 33: 851–856, 1999.
Bakris GL, Copley JB, Vicknair N, et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 50: 1641–1650, 1996.
Tuomilehto J, Ratenyte D, Birknhager WH, et al. for the Systolic Hypertension in Europe Trial Investigators. Effects of calcium channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 340: 677–684, 1999.
Hansson L, Zanchetti A, Carruther SG, et al. Effect of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. The Lancet 351: 1755–1762, 1997.
Zeller K, Whittaker E, Sullivan L, et al. Effect of dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Eng J Med 324: 78–84, 1991.
Klahr S, et al. The Effects of dietary protein restriction and BP control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Eng J Med 330: 877, 1994.
Brownlee M. Advanced protein glycosylation in diabetes and aging. Ann Rev Med 46: 223–234, 1995.
Soulis T, Cooper ME, Vranes D, Bucala R, Jerums G. Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. Kidney Int 50: 627–634, 1996.
Appel GB, Bolton K, Freedman B, Wuerth JP, Cartwright K, for the ACTION 1 Investigator Group. Pimagedine lowers total urinary protein and slows progression of overt diabetic nephropathy in patients with type 2 diabetes mellitus (abstract). J Am Soc Neph 10: 153A, 1999.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer Science+Business Media New York
About this chapter
Cite this chapter
Rosenstock, J.L., Appel, G.B. (2004). Diabetic Nephropathy. In: Poretsky, L. (eds) Principles of Diabetes Mellitus. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-6260-0_19
Download citation
DOI: https://doi.org/10.1007/978-1-4757-6260-0_19
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-6262-4
Online ISBN: 978-1-4757-6260-0
eBook Packages: Springer Book Archive